Akèy › Kasinòm epitelyal ovè › Pennsylvania
Etid klinik pou Kasinòm epitelyal ovè nan Pennsylvania
10 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Pennsylvania.
Vil nan Pennsylvania
Tèks ofisyèl etid la (Anglè)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, York
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- St. Lukes University Health Network, Bethlehem
- Ann B Barshinger Cancer Institute, Lancaster
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007CT-95 in Advanced Cancers Associated With Mesothelin Expression
- University of Pennsylvania, Philadelphia
- Context Investigational Site, Philadelphia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06756035A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Alliance Cancer Specialists, PC, Doylestown
- University of Pennsylvania, Philadelphia
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.